Work

140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.175

Authors: V. Guarneri, M.V. Dieci, G. Griguolo, L. Pare Brunet, M. Marin, F. Miglietta, M. Bottosso, C.A. Giorgi, P. Blasco, O. Castillo, P. Galván, P. Jares, J.A. Puig-butille, A. Vivancos, P. Villagrasa Gonzalez, J. Parker, C.M. Perou, P.F. Conte, A. Prat

Institutions: University of Padua, Istituto Oncologico Veneto, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Hospital Clínic de Barcelona, Vall d'Hebron Hospital Universitari, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Breast Cancer Research Foundation, Pfizer, Associazione Italiana per la Ricerca sul Cancro, Genentech, National Cancer Institute

OpenAlex ID: W4296007727

FWCI: 0.09

Cites: 2

Cited by: 1

Related to: 10